hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy

by Muratori, Leonardo, Petroni, Giulia, Antonuzzo, Lorenzo, Boni, Luca, Iorio, Jessica, Lastraioli, Elena, Bartoli, Gianluca, Messerini, Luca, Di Costanzo, Francesco, Arcangeli, Annarosa
Published in Onco Targets Ther (2016)

KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation

by Lastraioli, Elena, Antonuzzo, Lorenzo, Fantechi, Beatrice, Di Cerbo, Luisa, Di Costanzo, Alessandro, Lavacchi, Daniele, Armenio, Miriam, Arcangeli, Annarosa, Castiglione, Francesca, Messerini, Luca, Di Costanzo, Francesco
Published in Oncol Lett (2021)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)

by Giommoni, Elisa, Maiello, Evaristo, Vaccaro, Vanja, Rondini, Ermanno, Vivaldi, Caterina, Tortora, Giampaolo, Toppo, Laura, Giordano, Guido, Latiano, Tiziana Pia, Lamperini, Cinzia, Pillozzi, Serena, Boni, Luca, Antonuzzo, Lorenzo, Di Costanzo, Francesco
Published in Curr Oncol (2021)

Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study

by Salvianti, Francesca, Gelmini, Stefania, Mancini, Irene, Pazzagli, Mario, Pillozzi, Serena, Giommoni, Elisa, Brugia, Marco, Di Costanzo, Francesco, Galardi, Francesca, De Luca, Francesca, Castiglione, Francesca, Messerini, Luca, Pinzani, Pamela, Antonuzzo, Lorenzo
Published in Br J Cancer (2021)

Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study

by Antonuzzo, Lorenzo, Giommoni, Elisa, Pastorelli, Davide, Latiano, Tiziana, Pavese, Ida, Azzarello, Domenico, Aieta, Michele, Pastina, Ilaria, Di Fabio, Francesca, Bertolini, Alessandro, Corsi, Domenico Cristiano, Mogavero, Selene, Angelini, Valentina, Pazzagli, Mario, Di Costanzo, Francesco
Published in World J Gastroenterol (2015)

hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients()

by Iorio, Jessica, Lastraioli, Elena, Tofani, Lorenzo, Petroni, Giulia, Antonuzzo, Lorenzo, Messerini, Luca, Perrone, Giuseppe, Caputo, Damiano, Francesconi, Maria, Amato, Maria Michelina, Cadei, Moris, Arcangeli, Giuseppina, Villanacci, Vincenzo, Boni, Luca, Coppola, Roberto, Di Costanzo, Francesco, Arcangeli, Annarosa
Published in Transl Oncol (2020)

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors

by Berardi, Rossana, Torniai, Mariangela, Pusceddu, Sara, Spada, Francesca, Ibrahim, Toni, Brizzi, Maria Pia, Antonuzzo, Lorenzo, Ferolla, Piero, Panzuto, Francesco, Silvestris, Nicola, Partelli, Stefano, Ferretti, Benedetta, Freddari, Federica, Gucciardino, Calogero, Testa, Enrica, Concas, Laura, Murgioni, Sabina, Bongiovanni, Alberto, Zichi, Clizia, Riva, Nada, Rinzivillo, Maria, Brunetti, Oronzo, Giustini, Lucio, Di Costanzo, Francesco, Delle Fave, Gianfranco, Fazio, Nicola, De Braud, Filippo, Falconi, Massimo, Cascinu, Stefano
Published in Cancer Med (2017)